The German Federal Ministry of Education and Research (BMBF) is supporting the non-profit initiative 'Global Antibiotic Research & Development Partnership' with a further 50 million euros for the research and development of urgently needed, innovative antibiotics. The funding will allow GARDP to develop new treatments for drug-resistant infections and ensure they are available for every person who needs them. The announcement was made on the occasion of the World Health Summit in Berlin.
The German Federal Ministry of Education and Research (BMBF) is expanding its support for the non-profit organization „Global Antibiotic Research and Development Partnership“ (GARDP) to research and develop new antibiotics. An additional 50 million euros will be made available over the next 5 years (2023-2027) for the research and development of urgently needed, innovative antibiotic preparations. The GARDP also aims to ensure sustainable, equitable and affordable access to the newly developed antibiotics.
The Global Antibiotic Research and Development Partnership (GARDP), based in Switzerland, is a non-profit initiative founded in 2016 by the World Health Organization (WHO) and the „Drugs for Neglected Diseases initiative“ (DNDi) to research and develop new antibiotics. GARDP focuses on bacterial infectious diseases where antimicrobial resistance (AMR) is already present or where treatment is currently inadequate.
Federal Research Minister Bettina Stark-Watzinger explains:
"Multi-resistant bacteria pose an increasing threat to people worldwide. Even bacterial infections that were previously easy to treat can thus become life-threatening, as many antibiotics are no longer effective against such pathogens. I am therefore pleased that my House will support the 'Global Antibiotic Research and Development Partnership' with a further 50 million euros for the research and development of urgently needed, innovative antibiotics. This will ensure that Germany remains a strong and reliable international partner in the fight against multi-resistant bacteria. GARDP's goal is to develop five new therapies against drug-resistant infections by 2025."
Germany has been a strong supporter of GARDP since 2016, playing a leading role in efforts to combat antimicrobial resistance. With the additional funding, Germany remains the largest donor to GARDP, increasing its contributions to a total of 116 million Euro from a previous total of 61.7 million Euro over the past 4 years.
Further information at